Shuo Yang

Prof. Dr. Shuo Yang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in EBioMedicine
Verified
Journal Article
Open access
SYShuo Yang
Shuo Yang
SMSi-Qi Ma
Si-Qi Ma
XWXing Wan
Xing Wan
HHHeng He
Heng He
HPHan Pei
Han Pei
BLBin Li
Bin Li
Leber's hereditary optic neuropathy (LHON) is a disease that leads to blindness. Gene therapy has been investigated with some success, and could lead to important advancements in treating LHON. This was a prospective, open-label trial involving 9 LHON patients at Tongji Hospital, Wuhan, China, from August 2011 to December 2015. The purpose of this study was to evaluate the long-term outcomes of gene therapy for LHON. Nine LHON patients voluntarily received an intravitreal injection of rAAV2-ND4. Systemic examinations and visual function tests were performed during the 36-month follow-up period to determine the safety and efficacy of this gene therapy. Based on successful experiments in an animal model of LHON, 1 subject also received an rAAV2-ND4 injection in the second eye 12months after gene therapy was administered in the first eye. Recovery of visual acuity was defined as the primary outcome of this study. Changes in the visual field, visual evoked potential (VEP), optical coherence tomography findings, liver and kidney function, and antibodies against AAV2 were defined as secondary endpoints. Eight patients (Patients 2-9) received unilateral gene therapy and visual function improvement was observed in both treated eyes (Patients 4, 6, 7, and 8) and untreated eyes (Patients 2, 3, 4, 6 and 8). Visual regression fluctuations, defined as changes in visual acuity greater than or equal to 0.3 logMAR, were observed in Patients 2 and 9. Age at disease onset, disease duration, and the amount of remaining optic nerve fibers did not have a significant effect on the visual function improvement. The visual field and pattern reversal VEP also improved. The patient (Patient 1) who received gene therapy in both eyes had improved visual acuity in the injected eye after the first treatment. Unfortunately, visual acuity in this eye decreased 3months after he received gene therapy in the second eye. Animal experiments suggested that ND4 expression remains stable in the contralateral eye after intravitreal injections. No serious safety problem was observed in the 3-year follow-up of the 9 participants enrolled in this virus-based gene therapy. Meanwhile, our results support the use of intravitreal rAAV2-ND4 as an aggressive maneuver in our clinical trial. Further study in additional patients and in these 9 subjects is needed to better understand the effects of rAAV2-ND4 gene therapy on LHON and to increase the applications of this technique.

20 March 2017 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
SWShuaishuai Wang
Shuaishuai Wang
ZWZheng Wang
Zheng Wang
SYShuo Yang
Shuo Yang
TYTiemei Yin
Tiemei Yin
YZYaoli Zhang
Yaoli Zhang
Xufang SunXufang Sun
Xufang Sun
Purpose.This study was performed to measure the concentration oftrans-resveratrol and its three metabolites in human eyes.Methods.The patients who underwent pars plana vitrectomy for rhegmatogenous retinal detachment were included. The participants were orally giventrans-resveratrol-based supplement (Longevinex®). A suitable amount of conjunctiva, aqueous humor, and vitreous humor were obtained during the operation. High-performance liquid chromatography (HPLC) with mass spectrometry (LC/MS/MS) was used to detect the concentration oftrans-resveratrol and its three metabolites in the various samples.Results.The average concentration of resveratrol in the conjunctiva was 17.19 ± 15.32 nmol/g (mean ± SD). The concentration of resveratrol in the aqueous humor was close to the limit of detection, but its metabolites could be quantified. The concentrations of resveratrol metabolites in the aqueous humor can be detected. In the vitreous humor, the average concentration of resveratrol-3-O-sulfate was 62.95 ± 41.97 nmol/L. The sulfate conjugations of resveratrol were recovered in the conjunctiva, aqueous humor, and vitreous humor.Conclusions.Resveratrol and its three metabolites can be detected in the ocular tissues after oral administration. Although the concentration of parent resveratrol was low in the eyes, its metabolites could be detected and may have a role in the treatment of ocular diseases.

6 June 2024 in Postgraduate Medicine
Verified
Journal Article
Closed access
NWNing Wang
Ning Wang
SYShuo Yang
Shuo Yang
QGQi Gao
Qi Gao
Xiuming JinXiuming Jin
Xiuming Jin
Medical education is primarily based on practical schooling and the accumulation of experience and skills, which is important for the growth and development of young ophthalmic surgeons. However, present learning and refresher methods are constrained by several factors. Nevertheless, virtual reality (VR) technology has considerably contributed to medical training worldwide, providing convenient and practical auxiliary value for the selection of students' sub-majors. Moreover, it offers previously inaccessible surgical step training, scenario simulations, and immersive evaluation exams. This paper outlines the current applications of VR immersive teaching methods for ophthalmic surgery interns.

11 September 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CWChunyang Wang
Chunyang Wang
KYKelan Yuan
Kelan Yuan
YWYaying Wu
Yaying Wu
TJTao Jiang
Tao Jiang
YMYujie Mou
Yujie Mou
Xiuming JinXiuming Jin
Xiuming Jin

27 October 2025 in Eye and Vision
Verified
Journal Article
Open access
PDF file
KYKelan Yuan
Kelan Yuan
WYWu Yaying
Wu Yaying
CWChunyang Wang
Chunyang Wang
NWNing Wang
Ning Wang
YMYujie Mou
Yujie Mou
SYShuo Yang
Shuo Yang
Purpose: Diabetic keratopathy, a common ocular complication of diabetes, is characterized predominantly by corneal epithelial damage and peripheral nerve injury. This study examined the role of adiponectin (ADPN) in regulating the repair of the diabetic corneal epithelium and accompanying nerve injuries. Methods: RNA sequencing was performed on total RNA isolated from corneal epithelium of streptozotocin (STZ)-induced type 1 diabetic mice and type 2 diabetic BKS.Cg-Dock7m +/+ Leprdb/Nju (db/db) mice to identify differentially regulated pathways and interactions. ADPN receptor expression was assessed. Recombinant ADPN, ADPN receptor 1/2 siRNA, and a phosphorylated AKT (p-AKT) inhibitor were then utilized in diabetic mice and in human corneal epithelial cells (HCECs) cultured under high-glucose conditions to evaluate corneal wound healing responses. Results: ADPN receptor expression and p-AKT levels were downregulated in corneas of diabetic mice and in HCECs exposed to high glucose. Treatment with recombinant ADPN accelerated repair of corneal epithelial and nerve damage in both type 1 and type 2 diabetic mice, enhanced HCEC proliferation and migration under high-glucose conditions and activated AKT signaling. ADPN treatment also reduced neutrophil infiltration and inflammatory factor expression during wound repair. These beneficial effects were abolished by ADPN receptor 1 knockdown or AKT inhibition. Conclusions: Our results demonstrate that ADPN promotes the corneal epithelium and nerve regeneration in diabetic mice via activation of the AdipoR1/AKT signaling axis and suppression of inflammatory responses. These findings identify ADPN as a promising therapeutic candidate for promoting corneal epithelial wound healing in diabetic conditions.

10 February 2026 in The Ocular Surface
Verified
Journal Article
Closed access
KJKaifeng Jin
Kaifeng Jin
NWNing Wang
Ning Wang
CMChongyang Mou
Chongyang Mou
KYKelan Yuan
Kelan Yuan
CWChunyang Wang
Chunyang Wang
SYShuo Yang
Shuo Yang